Company intelligence / Profile preview

IMMY Funding

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Imprimis Pharmaceuticals focuses on the commercialization of novel compounded drug formulations, particularly injectable solutions for ophthalmology. Its lead products are designed to reduce post-operative eye drop use and their marketing includes the 'Go Dropless' campaign[3]. The company has also launched urology and pain management products, and seeks to commercialize through FDA’s Section 505(b)(2) pathway as well as through pharmacy compounding. Funding from IMMY Funding LLC was used to support commercialization and working capital needs[4].

Therapeutic areas: NeurologyMen's HealthOphthalmologyDermatology
Modalities: Compounded drug formulationInjectable solutionLyophilized powder
Industry: Investors

Partnerships

Life Sciences Alternative Funding (IMMY Funding LLC)

Beyond the preview

Go deeper on IMMY Funding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMMY Funding.

Explore the full profile